Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim N Chi

Showing results (51-60 of 234) with videos related to

Pageof 24
Sort By:
Clinical Genitourinary Cancer|July 5, 2014
A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancerSrikala S Sridhar, Anthony M Joshua, Richard Gregg, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 18, 2023
Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapySara Harsini, Don Wilson, Heather Saprunoff, et al.
Cancer|October 18, 2007
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancerGuru Sonpavde, Kim N Chi, Thomas Powles, et al.
JCO Precision Oncology|September 11, 2020
Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate CancerSinja Taavitsainen, Matti Annala, Elisa Ledet, et al.
World Journal of Urology|March 1, 2018
The impact of time to metastasis on overall survival in patients with prostate cancerSebastian Frees, Shusuke Akamatsu, Samir Bidnur, et al.
The Journal of Urology|July 21, 2016
AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone AcetateTilman Todenhöfer, Arun Azad, Craig Stewart, et al.
The Prostate|October 30, 2018
Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysisJean-Michel Lavoie, Kevin Zou, Daniel Khalaf, et al.
Journal of Translational Medicine|January 15, 2016
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trialRaya Leibowitz-Amit, Melania Pintilie, Leila Khoja, et al.
Investigational New Drugs|March 28, 2014
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancerArun A Azad, Emma K Beardsley, Sebastian J Hotte, et al.
Investigational New Drugs|November 29, 2021
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancerCorinne Maurice-Dror, Ronan Le Moigne, Ulka Vaishampayan, et al.
Pageof 24

Showing results (51-60 of 234) with videos related to

Sort By:
Pageof 24
Clinical Genitourinary Cancer|July 5, 2014
A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancerSrikala S Sridhar, Anthony M Joshua, Richard Gregg, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 18, 2023
Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapySara Harsini, Don Wilson, Heather Saprunoff, et al.
Cancer|October 18, 2007
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancerGuru Sonpavde, Kim N Chi, Thomas Powles, et al.
JCO Precision Oncology|September 11, 2020
Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate CancerSinja Taavitsainen, Matti Annala, Elisa Ledet, et al.
World Journal of Urology|March 1, 2018
The impact of time to metastasis on overall survival in patients with prostate cancerSebastian Frees, Shusuke Akamatsu, Samir Bidnur, et al.
The Journal of Urology|July 21, 2016
AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone AcetateTilman Todenhöfer, Arun Azad, Craig Stewart, et al.
The Prostate|October 30, 2018
Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysisJean-Michel Lavoie, Kevin Zou, Daniel Khalaf, et al.
Journal of Translational Medicine|January 15, 2016
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trialRaya Leibowitz-Amit, Melania Pintilie, Leila Khoja, et al.
Investigational New Drugs|March 28, 2014
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancerArun A Azad, Emma K Beardsley, Sebastian J Hotte, et al.
Investigational New Drugs|November 29, 2021
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancerCorinne Maurice-Dror, Ronan Le Moigne, Ulka Vaishampayan, et al.
Pageof 24